HDM3017 / Huadong Medicine - LARVOL DELTA

HDM3017‑1, a Potent and Selective STAT6 Degrader for the Treatment of Autoimmune and Inflammatory Diseases (EADV 2026) - "The clinical success of dupilumab, an approved injectable monoclonal antibody that blocks IL‑4/IL‑13 signaling for multiple atopic diseases, such as AD and asthma, further validates STAT6 as a promising therapeutic target...The efficacy of HDM3017‑1 was further assessed in a MC903‑induced atopic dermatitis model and a HDM-induced asthma model...Conclusions These findings confirm HDM3017-1 as a promising STAT6 degrader candidate for the treatment of autoimmune and inflammatory diseases, including atopic dermatitis and asthma. Supported by its potent STAT6 degradation activity as well as the anti-inflammatory activity, and favorable drug developability, HDM3017-1 is in the process of proceeding to IND-enabling development."

Asthma • Atopic Dermatitis • Dermatitis • Immunology • Inflammation • Respiratory Diseases • IL13 • IL4 • STAT6